T HIRTY-FIVE YEARS ago Dr William Dameshek, the first editor of the emerging journal
Blood, invited me to write a review on “The Hemolytic Effect of Primaquine.”'At the time …

In the present paper we have updated the G6PD mutations database, including all the last
discovered G6PD genetic variants. We underline that the last database has been published …

Abstract Glucose 6-phosphate dehydrogenase (G6PD) deficiency is 1 of the commonest
human enzymopathies, caused by inherited mutations of the X-linked gene G6PD. G6PD …

A total of 140 mutations or combination of mutations of the X-linked gene for glucose-6-
phosphate dehydrogenase are now known to us. Previous tabulations, providing somewhat …

Plasmodium vivax radical cure requires the use of primaquine (PQ), a drug that induces
haemolysis in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals, which …

Abstract Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency was discovered in the
1950s. The history of the development of knowledge about G6PD deficiency is reviewed …

Therapeutic utility of primaquine, an 8-aminoquinoline antimalarial drug, has been limited
due to its hemolytic toxicity in population with glucose 6-phosphate dehydrogenase …

Abstract Glucose‐6‐phosphate dehydrogenase (G6PD) is remarkable for its genetic
diversity in humans. Many variants of G6PD have been described with wide ranging levels …

Molecular abnormalities of erythroenzymopathies associated with hereditary hemolytic
anemia have been determined by means of molecular biology. Pyruvate kinase (PK) …

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, affecting an estimated 500 million
people worldwide, is a genetic disorder that causes human enzymopathies. Biochemical …